Ascendis Pharma AS to Post Q3 2016 Earnings of ($0.66) Per Share, Wedbush Forecasts (ASND)
Ascendis Pharma AS (NASDAQ:ASND) – Research analysts at Wedbush issued their Q3 2016 earnings estimates for Ascendis Pharma AS in a research note issued to investors on Monday. Wedbush analyst L. Moussatos forecasts that the brokerage will earn ($0.66) per share for the quarter. Wedbush currently has a “Outperform” rating and a $34.00 target price on the stock. Wedbush also issued estimates for Ascendis Pharma AS’s Q4 2016 earnings at ($0.66) EPS, FY2016 earnings at ($2.83) EPS, FY2017 earnings at ($2.63) EPS, FY2018 earnings at ($3.11) EPS, FY2019 earnings at ($3.93) EPS and FY2020 earnings at ($2.71) EPS.
Ascendis Pharma AS (NASDAQ:ASND) last released its quarterly earnings data on Wednesday, August 31st. The company reported ($0.59) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.69) by $0.10.
Several other analysts also recently issued reports on ASND. Zacks Investment Research raised Ascendis Pharma AS from a “sell” rating to a “hold” rating in a research note on Tuesday, July 26th. Leerink Swann reissued a “buy” rating on shares of Ascendis Pharma AS in a research note on Friday, September 2nd. Finally, TheStreet raised Ascendis Pharma AS from a “sell” rating to a “hold” rating in a research note on Tuesday, September 6th.
Shares of Ascendis Pharma AS (NASDAQ:ASND) opened at 20.31 on Wednesday. The stock’s market cap is $511.67 million. Ascendis Pharma AS has a 1-year low of $11.92 and a 1-year high of $21.70. The stock’s 50 day moving average price is $18.87 and its 200-day moving average price is $16.13.
Ascendis Pharma AS Company Profile
Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop a pipeline of long-acting prodrug therapies that address markets with unmet medical needs. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications.
Receive News & Stock Ratings for Ascendis Pharma AS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma AS and related stocks with our FREE daily email newsletter.